U.S. markets close in 5 minutes

Peer-reviewed data shows Gilead's drug effective against COVID-19 -NIH

May 22 (Reuters) - The National Institutes of Health (NIH) said on Friday peer-reviewed data published in the New England Journal of Medicine from a trial testing Gilead Sciences Inc's remdesivir showed the drug was superior to the standard of care for COVID-19.

Last month, the NIH announced early data from the study, which began in February with 1,063 participants in 10 countries.(https://bit.ly/2Tvd6I1) (Reporting by Manojna Maddipatla in Bengaluru; Editing by Aditya Soni)